Loading clinical trials...

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors

NCT02150525•Ohio State University Comprehensive Cancer Center

View on ClinicalTrials.gov

Summary

This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52). Omega-3 fatty acid may reduce inflammation and improve vaginal symptoms in postmenopausal breast cancer survivors.

Detailed Description

PRIMARY OBJECTIVES: I. To examine the ability of oral omega-3 fatty acids to improve symptoms of atrophic vaginitis as reported by postmenopausal breast cancer survivors as compared to survivors not taking omega 3. II.To examine the ability of oral omega-3 fatty acids to decrease inflammation related to atrophic vaginitis in postmenopausal breast cancer survivors as compared to survivors not taking omega 3. III. To examine the ability of oral omega-3 fatty acids to uptake systemically and to validate adherence; these measures will be compared to demographic data including body mass index to observe if differences exist in postmenopausal breast cancer survivors vs. those not taking omega 3. IV. To examine the effect of oral omega 3 fatty acids as compared to placebo of dietary supplement on serum female hormone levels in postmenopausal breast cancer survivors. V. To examine cytokine levels in women taking oral omega 3 fatty acids as compared to women not taking omega 3 to determine effect. OUTLINE: Patients were randomized to 1 of 2 treatment arms. ARM I: Patients received 3.5g omega-3 fatty acid orally (PO) daily for 6 months. ARM II: Patients received placebo of dietary supplement (7 capsules) PO daily for 6 months.

Eligibility

Age

45 - 65 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Woman with a history of breast cancer, stage 0, I, II, or III
•At least 12 months from definitive surgical procedure (i.e. lumpectomy or mastectomy)
•At least 3 months from completion of chemotherapy
•Postmenopausal, defined as no menstrual cycle for 12 consecutive months, or surgical menopause
•Have one or more stated symptoms of atrophic vaginitis, such as vaginal dryness, genital irritation/itching, genital pain, and/or dyspareunia
•No current use of estrogen replacement therapy
•If recent use of estrogen replacement therapy, off at least three months
•No current use of estradiol-releasing vaginal ring or estradiol vaginal tablets; if recent use of these products, off at least 3 consecutive months
•No evidence of disease (NED), any cancer other than breast cancer
•No current use of oral omega 3 fatty acids or Vitamin E; if recent consistent use of these products, off at least six months; if sporadic use of these products, off at least 3 consecutive months
+12 more criteria

Exclusion Criteria

•Metastatic malignancy of any kind
•Ongoing chemotherapy or radiation therapy (ongoing hormonal therapy and/or biologic therapy are allowed)
•History of pelvic or genital radiation therapy
•Use of Coumadin or other anticoagulants
•Known, active pelvic, vaginal, or urinary tract infections
•Current use of hormone replacement therapy, either systemic or local
•Uncontrolled co-morbidities including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable hypertension
•Psychiatric illness/social situation that would limit adherence to study requirements
•Consistent use of omega-3 fatty acid concentrates or capsules within the 6 months prior to entry on the study
•Known sensitivity or allergy to fish oil or omega 3 fish products
+2 more criteria

Locations (1)

The Ohio State University Medical Center, Comprehensive Breast Center

Columbus, Ohio, United States

Key Dates

Start Date

August 1, 2010

Primary Completion Date

January 1, 2013

Completion Date

January 1, 2013

Last Updated

August 9, 2018

Enrollment

ACTUAL participants

Conditions

Ductal Breast Carcinoma in SituBreast Cancer, Stage IBreast Cancer, Stage IIBreast Cancer, Stage III

Interventions

omega-3 fatty acid

DIETARY_SUPPLEMENT

placebo

OTHER

Questionnaire administration

BEHAVIORAL

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

NCT01905046

Atypical Ductal Breast HyperplasiaBRCA1 Mutation Carrier+3 more

View study

COMPLETEDPHASE2

The PROMISE Study: Duavee in Women With DCIS

NCT02694809

Ductal Breast Carcinoma In SituPostmenopausal

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

Inclusion Criteria

Exclusion Criteria

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

The PROMISE Study: Duavee in Women With DCIS

Broccoli Sprout Extract in Treating Patients With Breast Cancer

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ